A Study of CDPATH™ to Help Manage and Treat Crohn's Disease
- Conditions
- Crohn's Disease
- Interventions
- Other: CDPATH™Other: Blood Draw
- Registration Number
- NCT04809363
- Lead Sponsor
- Takeda
- Brief Summary
CDPATH™ is a tool to help predict the potential for developing Crohn's disease related complications in certain adult participants within 3 years. The main aim of the study is to explore the use of CDPATH™ to describe a participant's risk profile and to have discussions with their doctor about the potential path of their Crohn's disease. The number of visits will be decided by the study clinic according to their standard practice.
- Detailed Description
The tool being tested in this study is called CDPATH™. CDPATH™ is being used to provide a graphical representation of an individual participant's risk of developing a CD-related complication within three years, leveraging known participant risk factors based on clinical, serologic and genetic variables to help people categorize risk who have CD. This study will gather data on the use of the tool in real-world settings to inform practical use of CDPATH™.
The study will enroll approximately 200 patients. Participants and health care providers (HCPs) will be surveyed to understand their satisfaction with the CDPATH™ process and with their treatment choice.
This multi-center trial will be conducted in the United States. The overall time to participate in this study is 36 months. Participants will make multiple visits to the HCP's clinic, and data will be collected approximately every six months up to 3 years, based on the timing of routine follow-up appointments for assessment.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 200
- Has an initial diagnosis of CD established within five years prior to screening by clinical and endoscopic evidence and corroborated by a histopathology report (if available).
- Has agreed to use the CDPATH™ tool.
- Has reliable access to the internet and is willing to answer electronic patient-reported outcomes (ePROs) throughout the study.
- Has had known complications from CD including but not limited to: bowel stricture, CD-related intra-abdominal abscess, internal penetrating disease (known fistula other than perianal fistula), non-perianal surgery, bowel resection, or stricturoplasty. A perianal fistula or abscess without other signs of penetrating disease is allowed.
- Has had any non-CD-related abdominal surgery.
- Has received investigational biologic or nonbiologic agents for the treatment of CD in an investigational protocol. Approved biologic or nonbiologic agents for CD are allowed.
- Has previously used CDPATH™ or PROSPECT results to assess CD risk for complications.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description CDPATH™ CDPATH™ Participants with CD will be using CDPATH™ tool. Clinical data will be collected via an ongoing registry. Participants and health care provider (HCP)-reported outcomes data will be collected periodically once every 6 months for up to 36 months via electronic surveys. Two baseline blood samples will be collected at screening for CDPATH™ analysis. 1 additional sample will be collected for future potential biomarker analysis. CDPATH™ Blood Draw Participants with CD will be using CDPATH™ tool. Clinical data will be collected via an ongoing registry. Participants and health care provider (HCP)-reported outcomes data will be collected periodically once every 6 months for up to 36 months via electronic surveys. Two baseline blood samples will be collected at screening for CDPATH™ analysis. 1 additional sample will be collected for future potential biomarker analysis.
- Primary Outcome Measures
Name Time Method Percentage of Participants in Real-world Practice in Each Risk Category at Baseline Based on the CDPATH™ Tool Results Baseline (Day 1) The risk profile of an individual participant with CD is the output of the CDPATH™ tool. Categories for CD includes low, medium, high risk of developing a CD complication within 3 years.
- Secondary Outcome Measures
Name Time Method Change From Baseline in Decisional Conflict Scale (DCS) Score Baseline, then every 6 months up to 36 months DCS is a validated electronic patient-reported outcome (ePRO) collected via electronically administered patient surveys. It measures personal perceptions of the following responses: uncertainty in choosing options, modifiable factors contributing to uncertainty such as feeling uninformed, unclear about personal values and unsupported in decision making, and effective decision making such as feeling the choice is informed, values-based, likely to be implemented and expressing satisfaction with the choice. DCS involves answering 11 questions of PRO, of which 10 questions can be answered as yes (score = 0) or unsure (score = 2) or no (score =4). The total score will range from 0 to 40. Higher score indicates higher decisional conflict.
Percentage of Participants with Healthcare Resource Utilization Up to 36 months Healthcare resource includes healthcare provider (HCP) visits/referrals, visit to emergency room, hospitalizations, surgery, new CD-related complications, and diagnostic evaluations (e.g., imaging, colonoscopy, etc.).
Percentage of Participants with Specific Treatment Path and Choice Based on CDPATH™ Tool, Stratified According to Risk Category Up to 36 months Treatment path (i.e., sequence over time) and choice, by low, medium and high risk, will be chosen to characterize treatment path and choice based on risk stratification.
Change From Baseline in Work Productivity and Activity Impairment Questionnaire - CD Version (WPAI-CD) Score Baseline, then every 6 months up to 36 months WPAI-CD is a validated ePRO collected via electronically administered patient surveys. It consists of six questions that evaluate 4 domain scores: absenteeism (i.e., work time missed), presenteeism (i.e., reduced work productivity), overall work impairment, and activity impairment. Scores are expressed as a percentage of impairment, where higher scores indicate greater impairment and reduced productivity. The total score ranges from 0 (no impairment) to 100% (total loss of work productivity).
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health Scale Score Baseline, then every 6 months up to 36 months PROMIS Global Health scale is a validated ePRO collected via electronically administered patient surveys. It is a 10-item PRO measuring the overall evaluation of one's physical and mental health. The total score ranges from 0 to 100. The final score will be represented by the T-score metric, in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. A higher PROMIS T-score represents more of the concept being measured (higher Global Health score indicate better health).
Patient-Reported Satisfaction and Experience Score with the CDPATH™ Tool Up to 36 months Participant's satisfaction and experience with the CDPATH™ tool will be assessed based on 15 questions. Negative responses/lower score to/in these questions indicates less satisfaction whereas positive responses/higher score indicates satisfaction with the tool.
Number of Participants with Clinical Outcomes Up to 36 months Participants with clinical outcomes describing the disease burden based on treatment path and controlling for risk strata will be reported.
Change from First Assessment in Health Care Provider (HCP)-reported Assessment of the Feasibility and Usability of the CDPATH™ Tool First assessment (6 months after HCPs first enrolled participant) up to HCP leaves the study or the study ends (up to 36 months) HCP-reported CDPATH™ satisfaction data will be collected directly from HCPs via electronically administered HCP surveys and entered into the eCRF. HCPs will be queried regarding their satisfaction and experience with the general process, the ease of incorporating the tool in their everyday practice, and the impact of the tool on their treatment recommendations and participant communications. For the 6 questions, HCP will rate on 1-5 scale where, 1=strongly disagree and 5=strongly agree. For remaining 4 questions, written feedback from HCP will be consider. Overall positive responses will indicate higher feasibility and usability.
Trial Locations
- Locations (42)
Grand Teton Research Group, PLL
🇺🇸Idaho Falls, Idaho, United States
UMASS Memorial Medical Center
🇺🇸Worcester, Massachusetts, United States
Gastro Center of Maryland
🇺🇸Columbia, Maryland, United States
GI Alliance - Baton Rouge
🇺🇸Baton Rouge, Louisiana, United States
Lahey Clinic Inc. - PARENT ACCOUNT
🇺🇸Burlington, Massachusetts, United States
GCGA Physicians LLC
🇺🇸Fairfax, Virginia, United States
Allegheny Center for Digestive Health
🇺🇸Pittsburgh, Pennsylvania, United States
University of Pittsburgh Medical Center Health System
🇺🇸Pittsburgh, Pennsylvania, United States
West Central Gastroenterology d/b/a Gastro Florida
🇺🇸Clearwater, Florida, United States
Medical Research Center of Connecticut, LLC
🇺🇸Hamden, Connecticut, United States
University of California at Irvine Medical Center
🇺🇸Orange, California, United States
Gastroenterology Associates of Pensacola, PA
🇺🇸Pensacola, Florida, United States
Arizona Arthritis & Rheumatology Research, PLLC
🇺🇸Phoenix, Arizona, United States
Kaiser Permanate of Colorado
🇺🇸Aurora, Colorado, United States
Vanderbilt University Medical Center
🇺🇸Nashville, Tennessee, United States
The Oregon Clinic, P.C.
🇺🇸Portland, Oregon, United States
University of Utah
🇺🇸Salt Lake City, Utah, United States
Clinnova Research Solutions
🇺🇸Orange, California, United States
VA Loma Linda Healthcare System
🇺🇸Loma Linda, California, United States
University of Southern California Medical Center
🇺🇸Newport Beach, California, United States
United Medical Doctors
🇺🇸Murrieta, California, United States
GI Alliance
🇺🇸Bellevue, Washington, United States
Iowa Digestive Disease Center
🇺🇸Clive, Iowa, United States
University of Kansas Medical Center Research Institute, Inc.
🇺🇸Kansas City, Kansas, United States
University of Iowa Hospitals & Clinics
🇺🇸Iowa City, Iowa, United States
Rockford Gastroenterology Associates, Ltd.
🇺🇸Rockford, Illinois, United States
Comprehensive Gastrointestinal Health
🇺🇸Northbrook, Illinois, United States
Indiana University
🇺🇸Indianapolis, Indiana, United States
Louisiana Research Center, LLC
🇺🇸Shreveport, Louisiana, United States
Dayton Gastroenterology, Inc
🇺🇸Dayton, Ohio, United States
University of New Mexico
🇺🇸Albuquerque, New Mexico, United States
Clinical Inquest Center Ltd
🇺🇸Beavercreek, Ohio, United States
Lenox Hill Hospital
🇺🇸New York, New York, United States
Susquehanna Research Group, LLC
🇺🇸Camp Hill, Pennsylvania, United States
Palmetto Primary Care Physician Division of Gastroenterology
🇺🇸Summerville, South Carolina, United States
Rapid City Medical Center, LLC
🇺🇸Rapid City, South Dakota, United States
Frontier Clinical Research, LLC
🇺🇸Uniontown, Pennsylvania, United States
Baylor College of Medicine
🇺🇸Houston, Texas, United States
The University of Texas at Austin
🇺🇸Austin, Texas, United States
Care Access Research Berkley
🇺🇸Ogden, Utah, United States
GI Alliance - Southlake
🇺🇸Southlake, Texas, United States
Gastroenterology Associates
🇺🇸Lynchburg, Virginia, United States